Orchard Therapeutics (ORTX)
NASDAQ: ORTX
· Real-Time Price · USD
16.70
0.05 (0.30%)
At close: Jan 23, 2024, 10:00 PM
Orchard Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 21.84M | 21.31M | 18.37M | 22.66M | 16.15M | 11.57M | 7.2M | 1.68M | 1.19M | 2M | 2.6M |
Cost of Revenue | 2.4M | 2.3M | 1.23M | 2.43M | 4.34M | 2.92M | 1.8M | 226K | 226K | 667K | 858K |
Gross Profit | 19.44M | 19.02M | 17.14M | 20.22M | 11.81M | 8.65M | 5.4M | 1.45M | 969K | 1.33M | 1.74M |
Operating Income | 62.65M | 58.68M | 48.8M | 37.47M | -132.02M | -139.36M | -142.93M | -140.43M | -142.89M | -136.28M | -147.08M |
Interest Income | 4.78M | 3.68M | 2.5M | 1.54M | 749K | 410K | 310K | 412K | 628K | 1.1M | 1.88M |
Pretax Income | 70.96M | 56.66M | 17.8M | -9.01M | -180.25M | -169.18M | -153.9M | -143.76M | -141.07M | -124.32M | -135.9M |
Net Income | 69.86M | 57.61M | 19M | -7.88M | -179.13M | -168M | -153.7M | -144.58M | -141.86M | -125.7M | -136.59M |
Selling & General & Admin | 6.14M | 6.14M | 8.88M | 11.04M | 52.18M | 53.62M | 54.15M | 54.91M | 57.58M | 57.5M | 58.89M |
Research & Development | 4.48M | 8.03M | 13.3M | 25.55M | 91.65M | 94.39M | 94.18M | 86.98M | 86.28M | 80.11M | 89.93M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 10.63M | 14.17M | 22.18M | 36.59M | 143.83M | 148.01M | 148.33M | 141.88M | 143.86M | 137.61M | 148.82M |
Interest Expense | 3.8M | 3.66M | 3.36M | 3.08M | 2.83M | 2.71M | 2.63M | 2.5M | 2.39M | 2.28M | 2.25M |
Selling & Marketing Expenses | 3.44M | 3.59M | 4.2M | 4.13M | 4.83M | 5.42M | 4.93M | 5.26M | 6.54M | 6.25M | 7.05M |
Cost & Expenses | 13.02M | 16.47M | 23.41M | 39.02M | 148.17M | 150.93M | 150.13M | 142.11M | 144.08M | 138.27M | 149.68M |
Income Tax Expense | -847K | -955K | -1.2M | -1.13M | -1.12M | -1.17M | -201K | 828K | 789K | 1.38M | 691K |
Shares Outstanding (Basic) | 22.84M | 18.93M | 14.18M | 12.82M | 12.81M | 12.79M | 12.77M | 12.75M | 12.74M | 12.6M | 11.48M |
Shares Outstanding (Diluted) | 22.84M | 18.93M | 14.18M | 12.82M | 12.81M | 12.79M | 12.77M | 12.76M | 12.74M | 12.6M | 11.48M |
EPS (Basic) | 7.09 | 4.93 | 1.60 | -0.64 | -11.45 | -10.6 | -9.53 | -9.12 | -12.25 | -11.43 | -13.31 |
EPS (Diluted) | 7.09 | 4.93 | 1.60 | -0.64 | -11.45 | -10.6 | -9.53 | -9.12 | -12.25 | -11.43 | -13.31 |
EBITDA | 73M | 47.3M | 17.01M | -6.17M | -174.83M | -163.77M | -148.72M | -138.93M | -137.03M | -121.04M | -132.55M |
EBIT | -93.92M | -106.62M | -145.77M | -172.87M | -177.54M | -166.46M | -151.26M | -141.26M | -138.68M | -122.04M | -133.65M |
Depreciation & Amortization | 11M | -11.38M | -31.78M | -43.64M | -43.68M | -21.31M | -3.44M | 2.33M | 2.1M | 1.93M | 2.02M |